(P112) Spine Stereotactic Radiosurgery in the Treatment of Metastatic Pheochromocytoma: A Case Series

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Our data suggest that SSRS is an effective, safe, and durable treatment option. Given the robust tumor control of SSRS and the possibility for metastatic foci to serve as sources for further systemic spread, proactive treatment of spinal metastasis earlier in the disease course may offer therapeutic benefit to these patients.

Brian J. Deegan, MD, PhD, Amol J. Ghia, MD, Mary Frances McAleer, MD, PhD, Xin A. Wang, PhD, Paul D. Brown, MD, Jing Li, MD, PhD; UT MD Anderson Cancer Center

PURPOSE: Metastasis occurs in approximately 10% of all cases of pheochromocytoma and can cause significant morbidity and mortality. The axial skeleton is the most frequent site of these metastases. Since good systemic therapy options are lacking, local therapy remains the cornerstone of palliation for many of these patients. Due to the poor response of pheochromocytoma to standard fractionated radiotherapy, stereotactic radiosurgery (SRS) is an attractive option to overcome potential radioresistance and provide more durable local control (LC) of these tumors. Here, we report our institutional experience in the treatment of spine metastases from pheochromocytoma with spine SRS (SSRS).

METHODS: The available records of patients with metastatic pheochromocytoma treated with SSRS between 2000 and 2014 were retrospectively reviewed. Four patients with nine treated metastatic spinal lesions were identified. Follow-up spine magnetic resonance imaging (MRI) was used to evaluate LC. Pain and symptom data were assessed to evaluate toxicity. Kaplan-Meier method was used to assess LC and overall survival (OS).

RESULTS: Median age at time of SSRS was 55 years (range: 46–63 yr). Median follow-up for each treated site was 11 months (range: 4.5–54.6 mo). Treated areas included C-spine (22%), T-spine (33%), L-spine (33%), and sacrum (11%). The most common fractionation scheme was 27 Gy in three fractions (55.6%), followed by 24 Gy in one fraction (22.2%), 16 Gy in one fraction (11.1%), and 18 Gy in three fractions (11.1%). Crude LC rate was 100%, with no local treatment failures observed in the follow-up period. There were two patient deaths in the group (50%). The Kaplan-Meier OS from SSRS at 1 year was 75% and 50% at 2 years. Median time to SSRS from metastatic presentation was 17.6 months (range: 9.2–72.7 mo). Toxicities included pain (two cases), fatigue (two cases), and vertebral fracture (one case).

CONCLUSION: To our knowledge, this work is the first study describing the utility of SSRS in the treatment of metastatic pheochromocytoma. Our data suggest that SSRS is an effective, safe, and durable treatment option. Given the robust tumor control of SSRS and the possibility for metastatic foci to serve as sources for further systemic spread, proactive treatment of spinal metastasis earlier in the disease course may offer therapeutic benefit to these patients. Larger patient numbers and longer follow-up are required to address this issue more fully.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Related Content